September #27 : Roche Trap - by John Hammond

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Disability Dish

Not Working is a Full-Time Job

Task Mistress

Eppich Tale

Spree de Corps

Sharp as Attack


Roche Trap

Abnormal? Not to Worry!

Checking In

A Nose for Trouble

Let the Buyers Be Shared

Pulp Fiction...and Facts

Right Bulb

Disability Dish

Lovers Leap

Back to the Future

Periodic Problems

Data Jocks

Mate Expectations

Sex Matters

Debtor's Prison

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

September 1997

Roche Trap

by John Hammond

Hoffman-La Roche, maker of saquinavir (Invirase), stands accused of shoddy, if not shady, R&D. In August’s Tagline. The Treatment Action Group’s newsletter, Mark Harrington charges that even as the FDA approved its protease inhibitor in late 1995, the Swiss company was sitting on damaging data: The drug’s licensed dose—600 mg three times a day—is too low for optimal suppression of HIV and can quickly cause resistance.

“Had saquinavir become the drug of choice, a public-health disaster might well have resulted,” Harrington writes. “If cross-resistance became widespread, many would not be able to benefit from the later introduction of more potent protease inhibitors.”

The bigger blunder? Roche’s refusal to alert doctors and patients that only by quadrupling the dose is the drug safe and effective. But Roche calls the TAG rag’s tongue-lashing so much Monday-morning quarterbacking. “It’s easy to say how we might have done things better,” said medical director Dr. Laurent Fischer. “Saquinavir was the first protease inhibitor, and there was a demand for expanding access. It saved lives. Now we’re improving it.”

A tiger in the test tube, saquinavir has absorption hitches that earned it a rep as the runt of the protease litter. So Roche got busy developing a soft-gel-capsule that delivers eight times more drug. But now, says Harrington, a 1997 MacArthur “Genius” Fellowship winner, it’s payback time. Led by TAG and Project Inform, activists nationwide demand that Roche pull the ads for its current formulation, slash the price by seven-eights to reflect its actual potency and compensate cross-resistant consumers.

At presstime, the drug giant was a soft-gel-cap ad campaign and reportedly lobbying to get the new formulation named a first-line protease in the just-out federal standard-of-care guidelines.

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.